View ValuationDermapharm Holding 将来の成長Future 基準チェック /16Dermapharm Holding利益と収益がそれぞれ年間6.7%と3.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.1% 7.4%なると予測されています。主要情報6.7%収益成長率7.35%EPS成長率Pharmaceuticals 収益成長23.7%収益成長率3.8%将来の株主資本利益率18.12%アナリストカバレッジLow最終更新日21 May 2026今後の成長に関する最新情報Price Target Changed • Jun 27Price target decreased by 12% to €50.13Down from €56.90, the current price target is an average from 4 analysts. New target price is 38% above last closing price of €36.40. Stock is down 18% over the past year. The company is forecast to post earnings per share of €1.90 for next year compared to €1.16 last year.Price Target Changed • Mar 15Price target decreased by 9.9% to €56.40Down from €62.60, the current price target is an average from 5 analysts. New target price is 49% above last closing price of €37.84. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.58 for next year compared to €3.89 last year.Price Target Changed • Jan 07Price target decreased to €60.60Down from €65.33, the current price target is an average from 5 analysts. New target price is 67% above last closing price of €36.32. Stock is down 54% over the past year. The company is forecast to post earnings per share of €3.42 for next year compared to €3.89 last year.Price Target Changed • Nov 16Price target decreased to €64.60Down from €69.60, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €43.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €3.89 last year.Price Target Changed • Jan 05Price target increased to €102Up from €95.17, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €82.90. Stock is up 45% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €1.59 last year.Price Target Changed • Dec 17Price target increased to €98.50Up from €92.00, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €85.00. Stock is up 54% over the past year. The company is forecast to post earnings per share of €3.33 for next year compared to €1.59 last year.すべての更新を表示Recent updatesRecent Insider Transactions • May 20Chairman of the Supervisory Board recently bought €833m worth of stockOn the 14th of May, Wilhelm Beier bought around 18m shares on-market at roughly €46.83 per share. This transaction increased Wilhelm's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wilhelm has been a buyer over the last 12 months, purchasing a net total of €955m worth in shares.お知らせ • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.お知らせ • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.お知らせ • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.お知らせ • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026お知らせ • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.お知らせ • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023)Third quarter 2024 results: EPS: €0.60 (up from €0.46 in 3Q 2023). Revenue: €337.1m (up 17% from 3Q 2023). Net income: €32.4m (up 30% from 3Q 2023). Profit margin: 9.6% (up from 8.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.32 (up from €0.17 loss in 2Q 2023). Revenue: €292.6m (up 9.8% from 2Q 2023). Net income: €17.3m (up €26.5m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.Price Target Changed • Jun 27Price target decreased by 12% to €50.13Down from €56.90, the current price target is an average from 4 analysts. New target price is 38% above last closing price of €36.40. Stock is down 18% over the past year. The company is forecast to post earnings per share of €1.90 for next year compared to €1.16 last year.New Risk • May 19New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.0% net profit margin).お知らせ • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024Reported Earnings • Mar 29Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022)Full year 2023 results: EPS: €1.16 (down from €2.49 in FY 2022). Revenue: €1.19b (up 15% from FY 2022). Net income: €62.4m (down 54% from FY 2022). Profit margin: 5.2% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.Declared Dividend • Mar 17Dividend of €0.88 announcedShareholders will receive a dividend of €0.88. Ex-date: 6th June 2024 Payment date: 10th June 2024 Dividend yield will be 2.4%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 2 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024New Risk • Nov 19New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 180% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (180% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.1% net profit margin).Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022)Third quarter 2023 results: EPS: €0.46 (down from €0.98 in 3Q 2022). Revenue: €307.9m (up 16% from 3Q 2022). Net income: €24.8m (down 53% from 3Q 2022). Profit margin: 8.1% (down from 20% in 3Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 30Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022)Second quarter 2023 results: €0.17 loss per share (down from €0.27 profit in 2Q 2022). Revenue: €269.1m (up 11% from 2Q 2022). Net loss: €9.19m (down 163% from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €48.94, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €93.44 per share.Upcoming Dividend • Jun 08Upcoming dividend of €1.05 per share at 2.3% yieldEligible shareholders must have bought the stock before 15 June 2023. Payment date: 19 June 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.6%).Reported Earnings • Mar 30Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Price Target Changed • Mar 15Price target decreased by 9.9% to €56.40Down from €62.60, the current price target is an average from 5 analysts. New target price is 49% above last closing price of €37.84. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.58 for next year compared to €3.89 last year.Price Target Changed • Jan 07Price target decreased to €60.60Down from €65.33, the current price target is an average from 5 analysts. New target price is 67% above last closing price of €36.32. Stock is down 54% over the past year. The company is forecast to post earnings per share of €3.42 for next year compared to €3.89 last year.Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Price Target Changed • Nov 16Price target decreased to €64.60Down from €69.60, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €43.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €3.89 last year.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improved over the past weekAfter last week's 17% share price gain to €44.88, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €37.94, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 21% over the past three years.Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (2.6%).Reported Earnings • May 19First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 7.8%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 14Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Over the next year, revenue is forecast to grow 10%, compared to a 7.9% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jan 05Price target increased to €102Up from €95.17, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €82.90. Stock is up 45% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €1.59 last year.Price Target Changed • Dec 17Price target increased to €98.50Up from €92.00, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €85.00. Stock is up 54% over the past year. The company is forecast to post earnings per share of €3.33 for next year compared to €1.59 last year.お知らせ • Dec 16Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) for approximately €120 million on December 15, 2021. An upfront payment of €80 million, subject to customary cash and debt adjustments, will be made upon the closing of the transaction in addition to an earnout payment of up to €42.6 million subject to the achievement of select milestones by the C³ business. As part of the agreement, all C³ employees will be retained by Dermapharm following the closing of the transaction. Assuming timely receipt of required regulatory approvals and satisfaction of other closing conditions, the transaction is expected to close by January 31, 2022.Price Target Changed • Nov 18Price target increased to €94.17Up from €87.00, the current price target is an average from 6 analysts. New target price is 19% above last closing price of €78.85. Stock is up 58% over the past year. The company is forecast to post earnings per share of €3.49 for next year compared to €1.59 last year.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Nov 11Price target increased to €89.50Up from €82.30, the current price target is an average from 4 analysts. New target price is 11% above last closing price of €80.55. Stock is up 64% over the past year. The company is forecast to post earnings per share of €3.17 for next year compared to €1.59 last year.Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.8%).Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Apr 20Price target increased to €82.71Up from €76.60, the current price target is an average from 6 analysts. New target price is 12% above last closing price of €73.80. Stock is up 83% over the past year.Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.Price Target Changed • Apr 15Price target increased to €79.20Up from €73.00, the current price target is an average from 5 analysts. New target price is 7.3% above last closing price of €73.80. Stock is up 85% over the past year.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to €72.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €89.78 per share.Price Target Changed • Apr 09Price target increased to €76.60Up from €68.75, the current price target is an average from 5 analysts. New target price is 24% above last closing price of €61.95. Stock is up 61% over the past year.Price Target Changed • Mar 29Price target increased to €72.60Up from €67.25, the current price target is an average from 5 analysts. New target price is 16% above last closing price of €62.38. Stock is up 77% over the past year.Is New 90 Day High Low • Feb 13New 90-day high: €63.52The company is up 32% from its price of €48.24 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.02 per share.Is New 90 Day High Low • Jan 15New 90-day high: €60.63The company is up 38% from its price of €43.93 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.63 per share.Is New 90 Day High Low • Dec 29New 90-day high: €58.27The company is up 30% from its price of €44.99 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €71.08 per share.Valuation Update With 7 Day Price Move • Nov 25Market bids up stock over the past weekAfter last week's 19% share price gain to €55.05, the stock is trading at a trailing P/E ratio of 34.5x, up from the previous P/E ratio of 29.2x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past year are 44%.Is New 90 Day High Low • Nov 20New 90-day high: €50.44The company is up 19% from its price of €42.49 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.65 per share.Price Target Changed • Nov 19Price target raised to €54.00Up from €50.33, the current price target is an average from 4 analysts. The new target price is 8.3% above the current share price of €49.85. As of last close, the stock is up 37% over the past year.Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS €0.42The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: €208.8m (up 12% from 3Q 2019). Net income: €22.7m (up 18% from 3Q 2019). Profit margin: 11% (in line with 3Q 2019).Analyst Estimate Surprise Post Earnings • Nov 17Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 11%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 16% share price gain to €49.13, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 27.9x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past year are 42%.Is New 90 Day High Low • Oct 29New 90-day low: €40.88The company is down 4.0% from its price of €42.72 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €61.41 per share.Is New 90 Day High Low • Oct 05New 90-day high: €47.33The company is up 2.0% from its price of €46.34 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €62.88 per share.業績と収益の成長予測DB:DMP - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,299172201254412/31/20271,255154188241512/31/20261,20813919424553/31/20261,182144241285N/A12/31/20251,178132187229N/A9/30/20251,174116164207N/A6/30/20251,191107175216N/A3/31/20251,199104131173N/A12/31/20241,195114163201N/A9/30/20241,17491157197N/A6/30/20241,14783146187N/A3/31/20241,12957137179N/A12/31/20231,15162178219N/A9/30/20231,17295240279N/A6/30/20231,151123267304N/A3/31/20231,128146287323N/A12/31/20221,041134250289N/A9/30/20221,024176222269N/A6/30/20221,004185191249N/A3/31/2022980211190252N/A12/31/2021960210189250N/A9/30/2021902162153209N/A6/30/2021858123115164N/A3/31/20218289596139N/A12/31/20208088690131N/A9/30/20207758060104N/A6/30/2020760775897N/A3/31/20207438569114N/A12/31/201971477N/A101N/A9/30/201967473N/A90N/A6/30/201963977N/A109N/A3/31/201961173N/A115N/A12/31/201858475N/A159N/A9/30/201855875N/A165N/A6/30/201852576N/A137N/A3/31/201849879N/A120N/A12/31/201748078N/A87N/A9/30/201748684N/A84N/A12/31/201645577N/A77N/A12/31/201539613N/A40N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DMPの予測収益成長率 (年間6.7% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: DMPの収益 ( 6.7% ) German市場 ( 17.1% ) よりも低い成長が予測されています。高成長収益: DMPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: DMPの収益 ( 3.8% ) German市場 ( 6.8% ) よりも低い成長が予測されています。高い収益成長: DMPの収益 ( 3.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DMPの 自己資本利益率 は、3年後には低くなると予測されています ( 18.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 08:38終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dermapharm Holding SE 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Gerhard OrgonasBerenbergFabian PiastaJefferies LLCMartin ComtesseJefferies LLC9 その他のアナリストを表示
Price Target Changed • Jun 27Price target decreased by 12% to €50.13Down from €56.90, the current price target is an average from 4 analysts. New target price is 38% above last closing price of €36.40. Stock is down 18% over the past year. The company is forecast to post earnings per share of €1.90 for next year compared to €1.16 last year.
Price Target Changed • Mar 15Price target decreased by 9.9% to €56.40Down from €62.60, the current price target is an average from 5 analysts. New target price is 49% above last closing price of €37.84. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.58 for next year compared to €3.89 last year.
Price Target Changed • Jan 07Price target decreased to €60.60Down from €65.33, the current price target is an average from 5 analysts. New target price is 67% above last closing price of €36.32. Stock is down 54% over the past year. The company is forecast to post earnings per share of €3.42 for next year compared to €3.89 last year.
Price Target Changed • Nov 16Price target decreased to €64.60Down from €69.60, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €43.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €3.89 last year.
Price Target Changed • Jan 05Price target increased to €102Up from €95.17, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €82.90. Stock is up 45% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €1.59 last year.
Price Target Changed • Dec 17Price target increased to €98.50Up from €92.00, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €85.00. Stock is up 54% over the past year. The company is forecast to post earnings per share of €3.33 for next year compared to €1.59 last year.
Recent Insider Transactions • May 20Chairman of the Supervisory Board recently bought €833m worth of stockOn the 14th of May, Wilhelm Beier bought around 18m shares on-market at roughly €46.83 per share. This transaction increased Wilhelm's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wilhelm has been a buyer over the last 12 months, purchasing a net total of €955m worth in shares.
お知らせ • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
お知らせ • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.
お知らせ • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026
お知らせ • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.
お知らせ • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023)Third quarter 2024 results: EPS: €0.60 (up from €0.46 in 3Q 2023). Revenue: €337.1m (up 17% from 3Q 2023). Net income: €32.4m (up 30% from 3Q 2023). Profit margin: 9.6% (up from 8.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.32 (up from €0.17 loss in 2Q 2023). Revenue: €292.6m (up 9.8% from 2Q 2023). Net income: €17.3m (up €26.5m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
Price Target Changed • Jun 27Price target decreased by 12% to €50.13Down from €56.90, the current price target is an average from 4 analysts. New target price is 38% above last closing price of €36.40. Stock is down 18% over the past year. The company is forecast to post earnings per share of €1.90 for next year compared to €1.16 last year.
New Risk • May 19New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.0% net profit margin).
お知らせ • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024
Reported Earnings • Mar 29Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022)Full year 2023 results: EPS: €1.16 (down from €2.49 in FY 2022). Revenue: €1.19b (up 15% from FY 2022). Net income: €62.4m (down 54% from FY 2022). Profit margin: 5.2% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.
Declared Dividend • Mar 17Dividend of €0.88 announcedShareholders will receive a dividend of €0.88. Ex-date: 6th June 2024 Payment date: 10th June 2024 Dividend yield will be 2.4%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024
New Risk • Nov 19New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 180% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (180% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.1% net profit margin).
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022)Third quarter 2023 results: EPS: €0.46 (down from €0.98 in 3Q 2022). Revenue: €307.9m (up 16% from 3Q 2022). Net income: €24.8m (down 53% from 3Q 2022). Profit margin: 8.1% (down from 20% in 3Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 30Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022)Second quarter 2023 results: €0.17 loss per share (down from €0.27 profit in 2Q 2022). Revenue: €269.1m (up 11% from 2Q 2022). Net loss: €9.19m (down 163% from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €48.94, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €93.44 per share.
Upcoming Dividend • Jun 08Upcoming dividend of €1.05 per share at 2.3% yieldEligible shareholders must have bought the stock before 15 June 2023. Payment date: 19 June 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.6%).
Reported Earnings • Mar 30Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Price Target Changed • Mar 15Price target decreased by 9.9% to €56.40Down from €62.60, the current price target is an average from 5 analysts. New target price is 49% above last closing price of €37.84. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.58 for next year compared to €3.89 last year.
Price Target Changed • Jan 07Price target decreased to €60.60Down from €65.33, the current price target is an average from 5 analysts. New target price is 67% above last closing price of €36.32. Stock is down 54% over the past year. The company is forecast to post earnings per share of €3.42 for next year compared to €3.89 last year.
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Nov 16Price target decreased to €64.60Down from €69.60, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €43.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €3.89 last year.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improved over the past weekAfter last week's 17% share price gain to €44.88, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €37.94, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 21% over the past three years.
Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (2.6%).
Reported Earnings • May 19First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 7.8%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 14Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Over the next year, revenue is forecast to grow 10%, compared to a 7.9% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jan 05Price target increased to €102Up from €95.17, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €82.90. Stock is up 45% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €1.59 last year.
Price Target Changed • Dec 17Price target increased to €98.50Up from €92.00, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €85.00. Stock is up 54% over the past year. The company is forecast to post earnings per share of €3.33 for next year compared to €1.59 last year.
お知らせ • Dec 16Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) for approximately €120 million on December 15, 2021. An upfront payment of €80 million, subject to customary cash and debt adjustments, will be made upon the closing of the transaction in addition to an earnout payment of up to €42.6 million subject to the achievement of select milestones by the C³ business. As part of the agreement, all C³ employees will be retained by Dermapharm following the closing of the transaction. Assuming timely receipt of required regulatory approvals and satisfaction of other closing conditions, the transaction is expected to close by January 31, 2022.
Price Target Changed • Nov 18Price target increased to €94.17Up from €87.00, the current price target is an average from 6 analysts. New target price is 19% above last closing price of €78.85. Stock is up 58% over the past year. The company is forecast to post earnings per share of €3.49 for next year compared to €1.59 last year.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Nov 11Price target increased to €89.50Up from €82.30, the current price target is an average from 4 analysts. New target price is 11% above last closing price of €80.55. Stock is up 64% over the past year. The company is forecast to post earnings per share of €3.17 for next year compared to €1.59 last year.
Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.8%).
Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Apr 20Price target increased to €82.71Up from €76.60, the current price target is an average from 6 analysts. New target price is 12% above last closing price of €73.80. Stock is up 83% over the past year.
Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
Price Target Changed • Apr 15Price target increased to €79.20Up from €73.00, the current price target is an average from 5 analysts. New target price is 7.3% above last closing price of €73.80. Stock is up 85% over the past year.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to €72.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €89.78 per share.
Price Target Changed • Apr 09Price target increased to €76.60Up from €68.75, the current price target is an average from 5 analysts. New target price is 24% above last closing price of €61.95. Stock is up 61% over the past year.
Price Target Changed • Mar 29Price target increased to €72.60Up from €67.25, the current price target is an average from 5 analysts. New target price is 16% above last closing price of €62.38. Stock is up 77% over the past year.
Is New 90 Day High Low • Feb 13New 90-day high: €63.52The company is up 32% from its price of €48.24 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.02 per share.
Is New 90 Day High Low • Jan 15New 90-day high: €60.63The company is up 38% from its price of €43.93 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.63 per share.
Is New 90 Day High Low • Dec 29New 90-day high: €58.27The company is up 30% from its price of €44.99 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €71.08 per share.
Valuation Update With 7 Day Price Move • Nov 25Market bids up stock over the past weekAfter last week's 19% share price gain to €55.05, the stock is trading at a trailing P/E ratio of 34.5x, up from the previous P/E ratio of 29.2x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past year are 44%.
Is New 90 Day High Low • Nov 20New 90-day high: €50.44The company is up 19% from its price of €42.49 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.65 per share.
Price Target Changed • Nov 19Price target raised to €54.00Up from €50.33, the current price target is an average from 4 analysts. The new target price is 8.3% above the current share price of €49.85. As of last close, the stock is up 37% over the past year.
Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS €0.42The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: €208.8m (up 12% from 3Q 2019). Net income: €22.7m (up 18% from 3Q 2019). Profit margin: 11% (in line with 3Q 2019).
Analyst Estimate Surprise Post Earnings • Nov 17Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 11%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 16% share price gain to €49.13, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 27.9x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past year are 42%.
Is New 90 Day High Low • Oct 29New 90-day low: €40.88The company is down 4.0% from its price of €42.72 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €61.41 per share.
Is New 90 Day High Low • Oct 05New 90-day high: €47.33The company is up 2.0% from its price of €46.34 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €62.88 per share.